Search results for "MYOPATHY"

showing 10 items of 352 documents

Alcohol puts the heart under pressure: Acetaldehyde activates a localized renin angiotensin aldosterone system within the myocardium in alcoholic car…

2018

medicine.medical_specialtyCardiomyopathyAlcoholBlood PressureAcetaldehyde030204 cardiovascular system & hematologyAlcoholic cardiomyopathyRenin-Angiotensin System03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineRenin–angiotensin systemReninmedicineHumans030212 general & internal medicineEthanolEthanolbusiness.industryAngiotensin IICardiomyopathy AlcoholicMyocardiumAcetaldehydemedicine.diseaseAngiotensin IIEndocrinologyBlood pressurechemistryCardiology and Cardiovascular MedicinebusinessInternational journal of cardiology
researchProduct

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without typ…

2020

Abstract Aims The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise ability and patient-reported outcomes in heart failure (HF) with reduced and preserved ejection fraction (EF), with and without type 2 diabetes (T2D), reporting, for the first time, the effects of sodium-glucose co-transporter-2 inhibition in HF with preserved EF (HFpEF). Methods and results HF patients with reduced EF (HFrEF) (≤40%, N = 312, EMPERIAL-Reduced) or preserved EF (>40%, N = 315, EMPERIAL-Preserved), with and without T2D, were randomized to empagliflozin 10 mg or placebo for 12 weeks. The …

medicine.medical_specialtyCardiomyopathyType 2 diabetes030204 cardiovascular system & hematologyPlacebo03 medical and health sciences0302 clinical medicineGlucosidesInternal medicinemedicineClinical endpointEmpagliflozinHumans030212 general & internal medicineBenzhydryl CompoundsHeart FailureEjection fractionSurrogate endpointbusiness.industryStroke Volumemedicine.diseaseDiabetes Mellitus Type 2Heart failureCardiologyCardiology and Cardiovascular MedicinebusinessEuropean heart journal
researchProduct

Treatment of Tako-tsubo cardiomyopathy

2008

N.A.

medicine.medical_specialtyCardiotonic AgentsHeart diseasebusiness.industryCardiomyopathyTako-tsubo Cardiomyopathymedicine.diseaseTako-tsubo cardiomyopathyTakotsubo CardiomyopathyInternal medicinePractice Guidelines as TopicACE inhibitormedicineCardiologyHumansMyocardial diseaseCardiology and Cardiovascular MedicinebusinessBeta (finance)medicine.drugInternational Journal of Cardiology
researchProduct

Anthrazyklin-induzierte Kardiotoxizität: MRT des Herzens bei Kindern und Jugendlichen mit malignen Erkrankungen

2004

Purpose: Quantification of left and right ventricular function using MRI in young cancer patients treated with cardiotoxic anthracyclines. Materials and Methods: Twenty-eight patients (mean age 16.4 years) underwent cardiac MRI at 1.5 T. The study protocol consisted of morphologic T2-weighted images with fat suppression and cine steady-state free precession sequences (SSFP) for functional analysis. Seven patients were examined at the end of chemotherapy, two of them also repeatedly during therapy, and 21 patients following an average period of three years after finishing chemotherapy (range one month - 20 years) Results: The end-systolic volume index increased and the ejection fraction of t…

medicine.medical_specialtyCardiotoxicityChemotherapyEjection fractionAnthracyclinebusiness.industrymedicine.medical_treatmentCardiomyopathyCancerSteady-state free precession imagingmedicine.diseaseSurgerymedicine.anatomical_structureVentricleInternal medicinemedicineCardiologyRadiology Nuclear Medicine and imagingbusinessRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
researchProduct

Chronic stress and early recurrence of takotsubo cardiomyopathy: A clinical case

2014

Takotsubo cardiomyopathy (TC) is characterized by transient systolic dysfunction of the apical and middle segments of the left ventricle, accompanied by electrocardiographic abnormalities and mild elevation of cardiac biomarker levels in the absence of obstructive coronary artery disease. The following case is of a woman suffering from chronic emotional stress with a very early recurrence. An acute trigger event was not detectable in both cases. It is possible to suppose that, in predisposed subjects, chronic stress by increasing sympathetic activity may be considered not only a trigger for TC, but also a negative prognostic factor for early recurrence.

medicine.medical_specialtyEarly Recurrencebusiness.industryCardiomyopathyCase Reportmedicine.diseaseCoronary artery diseasechronic stremyocardial infarctionmedicine.anatomical_structureVentricleInternal medicinemedicineCardiologyBiomarker (medicine)Radiology Nuclear Medicine and imagingChronic stressTakotsubo cardiomyopathyClinical caseMyocardial infarctionCardiology and Cardiovascular Medicinebusinesschronic stressJournal of Cardiovascular Echography
researchProduct

0137 : Takotsubo cardiomyopathy following acute cerebral events

2016

International audience; ObjectiveTakotsubo cardiomyopathy is characterized by a transient apical ventricular dysfunction typically induced by an acute stress. Acute cerebral events including ischemic stroke (IS) or Epileptic Event (EE) may both be associated with massive catecholamine release. We aimed to identify the characteristics and outcomes of patients who experienced Takotsubo syndrome complicating an IS or EE.MethodsBetween 2008 and 2013, 87 patients were admitted in our Intensive Care Unit for suspected Takotsubo syndrome, of whom 6 previously experienced acute cerebral symptoms with either IS or EE, within two days. Takotsubo syndrome was diagnosed on Cardiac Magnetic Resonance, e…

medicine.medical_specialtyEjection fractionbiologybusiness.industryCardiomyopathy[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseaseTransient apical ventricular dysfunctionCulpritTroponinHemiparesis[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Heart failureT waveInternal medicinemedicinebiology.proteinCardiologyST segmentTakotsubo cardiomyopathymedicine.symptombusinessCardiology and Cardiovascular MedicineComputingMilieux_MISCELLANEOUSArchives of Cardiovascular Diseases Supplements
researchProduct

Left ventricular non-compaction cardiomyopathy in children: Is segmental fibrosis the cause of tissue Doppler alterations and of EF reduction?

2009

Noncompaction of the ventricular myocardium (LVNC) is a rare congenital cardiomyopathy resulting from an arrest in normal endomyocardial embryogenesis. In 2002 Jenni et al. [Jenni R, Wyss CA, Oechslin EN, Kaufmann PA. Isolated ventricular noncompaction is associated with coronary microcirculatory dysfunction. J Am Coll Cardiol 2002; 39:450-454.] reported a microvascular dysfunction in 12 patients affected by non compaction: areas of restricted myocardial perfusion have been documented by scintigraphy, suggesting a reduction of Coronary flow reserve. McMahon et al reported in a recent article a reduction of TD velocities in children with noncompaction of the left ventricle, compared with nor…

medicine.medical_specialtyEjection fractionmedicine.diagnostic_testbusiness.industryHeart VentriclesCardiomyopathyCoronary flow reserveStroke VolumeScintigraphymedicine.diseaseFibrosisEchocardiography DopplerTransplantationmedicine.anatomical_structureLeft ventricular non-compactionVentricleFibrosisInternal medicineCardiologymedicineHumansCardiology and Cardiovascular MedicinebusinessCardiomyopathiesPerfusion
researchProduct

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

2015

Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease. Data were extracted from FOS, a Shire-sponsored database, for comparison with data from three published studies. Outcomes evaluated were the annualized rate of change in estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) as well as time to and ages at a composite morbidity endpoint and at death. FOS data were extracted for 740 treated patients who were followed for a median of ~ 5 years. Compared with no trea…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismUrologyCardiomyopathyRenal functionSE Standard errorLeft ventricular hypertrophyBiochemistryLVH Left ventricular hypertrophyLong-term effectivenessEndocrinologyGeneticsMedicineMDRD Modification of Diet in Renal Diseaselcsh:QH301-705.5Molecular BiologyAgalsidase alfaeGFR Estimated glomerular filtration rateFabry diseaselcsh:R5-920CI Confidence intervalbusiness.industryEnzyme replacement therapymedicine.diseaseEgfr Estimated glomerular filtration rateFabry diseaseSurgeryARB Angiotensin receptor blockerSEM Standard error of the meanStandard errorlcsh:Biology (General)SI:TherapyEnzyme replacement therapyCohortFOS Fabry Outcome SurveyLVMI Left ventricular mass indexed to heightlcsh:Medicine (General)businessACEI Angiotensin-converting enzyme inhibitorAgalsidase alfaERT Enzyme replacement therapyMolecular Genetics and Metabolism Reports
researchProduct

Filamin C variants are associated with a distinctive clinical and immunohistochemical arrhythmogenic cardiomyopathy phenotype.

2020

Background: Pathogenic variants in the filamin C (FLNC) gene are associated with inherited cardiomyopathies including dilated cardiomyopathy with an arrhythmogenic phenotype. We evaluated FLNC variants in arrhythmogenic cardiomyopathy (ACM) and investigated the disease mechanism at a molecular level. Methods: 120 gene-elusive ACM patients who fulfilled diagnostic criteria for arrhythmogenic right ventricular cardiomyopathy (ARVC) were screened by whole exome sequencing. Fixed cardiac tissue from FLNC variant carriers who had died suddenly was investigated by histology and immunohistochemistry. Results: Novel or rare FLNC variants, four null and five variants of unknown significance, were id…

medicine.medical_specialtyFilaminsCardiomyopathyContrast MediaGadolinium030204 cardiovascular system & hematologyVentricular tachycardiaSudden deathRight ventricular cardiomyopathy03 medical and health sciences0302 clinical medicineCardiac magnetic resonance imagingInternal medicinemedicineHumansCor030212 general & internal medicineFLNCcardiovascular diseasesArrhythmogenic Right Ventricular DysplasiaExome sequencingmedicine.diagnostic_testbusiness.industryDilated cardiomyopathymedicine.diseasePatologiaPhenotypeMutationCardiologyCardiomyopathiesCardiology and Cardiovascular Medicinebusiness
researchProduct

Myocardial fibrosis by delayed enhancement cardiovascular magnetic resonance and HCV infection in thalassemia major patients.

2010

Abstract Abstract 4265 Introduction. Delayed enhancement (DE) cardiac magnetic resonance (CMR) technique with intravenous administration of gadolinium (Gd) chelates contrast agents is the only validated non-invasive approach for detecting myocardial fibrosis (Mahrholdt H et al, Eur Heart J 2005). This technique has been confirmed safe in patients with hemoglobinopathies (Meloni A et al, Haematologica 2009). In thalassemia major (TM), myocardial fibrosis has been detected using the DE technique and a positive correlation with anti-HCV antibodies has been described (Pepe A et al, Heart 2009). However, HCV-induced cardiomyopathy is still controversial (Matsumori A et al. J Card Fail 2006). The…

medicine.medical_specialtyHepatitis C virusThalassemiaImmunologyCardiomyopathymedicine.disease_causeBiochemistryGastroenterologyGadobutrolPathogenesisInternal medicineMyocardial fibrosisMedicinemedicine.diagnostic_testbusiness.industryMyocardial fibrosis; HCV infection; Thalassemia MajorRetrospective cohort studyMagnetic resonance imagingCell BiologyHematologymedicine.diseaseSurgeryHCV infectionMyocardial fibrosisbusinessThalassemia Majormedicine.drug
researchProduct